サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1247444

経頭蓋磁気刺激装置の世界市場-2023-2030

Global Transcranial Magnetic Stimulator Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
経頭蓋磁気刺激装置の世界市場-2023-2030
出版日: 2023年03月28日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

経頭蓋磁気刺激装置の世界市場規模は、2022年に11億2,525万米ドル、2030年には22億4,479万米ドルに達すると推定され、予測期間（2023-2030年）に9.2%のCAGRで成長すると予測されています。

経頭蓋磁気刺激療法は、大うつ病、アルツハイマー病、パーキンソン病、その他の神経疾患に関連する脳領域の神経細胞を引き出すために短い磁気パルスを適用することを含む非侵襲的な技術的ブレークスルーです。

市場力学

老年人口の増加や加齢に伴う神経疾患の増加、製品の発売や承認が、予測期間中の経頭蓋磁気神経刺激市場の世界成長を後押ししています。

多数の製品の発売と承認が、予測期間の世界市場成長を促進します。

製品の発売や承認などの市場開拓が、予測期間中の経頭蓋磁気刺激装置の世界市場の成長を後押ししています。例えば、2022年7月、FDAは、大うつ病性障害の人の不安症状を治療するための経頭蓋磁気刺激装置であるNeuronetics社のNeuroStar Advanced Therapy for Mental Healthを承認しました。同様に、2021年8月、米国FDAは、不安性うつ病とも呼ばれる成人患者のうつ病に併存する不安症状を軽減するために、メンタルヘルス症状に対する高度な非侵襲的神経刺激治療のサプライヤーであるBrainsWay Ltd.に対してDeep Transcranial Magnetic Stimulation（Deep TMS）Systemマーケティング許可を承認しました。同様に、2020年8月には、強迫性障害（OCD）の併用療法として、マグベンチャー社のTMSセラピーにFDAが認可を与えました。デンマークの医療機器メーカーであるMagVenture社にとって、米国で2番目の適応となります。

さらに、2021年11月には、神経科学を基盤としたメンタルヘルスケアと研究を行うマグスティムが、Horizon 3.0の510Kクリアランスを取得しました。Horizon 3.0は、特に臨床現場向けに設計されているため、ナビゲートされたTMSとアナリティクスで強化されたワークフローを提供します。また、Magstim Connectは、TMSのためのユニークで集中的な患者データ管理ソリューションであり、近い将来、市場の成長を促進すると予想されています。したがって、製品の承認や発売の増加が、予測期間中の経頭蓋磁気刺激装置の世界市場を後押ししています。

TMSのコストが高いことが、経頭蓋磁気刺激装置の世界市場の成長を抑制すると思われます。

しかし、経頭蓋磁気刺激装置の高コストが、予測期間中の世界市場の成長を抑制すると思われます。例えば、TMSマシンは6万米ドルもするため、ほとんどの個人または開業医は購入できず、予測期間中の世界市場の成長を阻害します。

COVID-19のインパクト

COVID-19は、パンデミックが需要と生産に直接影響を与え、企業の財政負担を増加させたため、世界の経頭蓋磁気刺激装置市場に大きな影響を与えました。パンデミックの間、COVID-19の蔓延を止めるために神経学的処置が頻繁に延期または中止されました。最も影響を受けた米国、ロシア、インド、ブラジル、フランス、英国、イタリア、スペインでは、脳神経外科手術が約55％減少しました。COVID-19ウイルスは心臓、肺、脳に害を及ぼす可能性があり、長期的な健康問題が発生する可能性があります。しかし、COVID-19は、社会的孤立によるうつ病や不安症の症例を増加させ、パンデミックの負の影響をいくらか中和しています。

目次

  • 調査手法
  • 調査目的および調査範囲について

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 大量の製品の発売と承認
      • 老年人口とそれに伴う神経疾患の増加
    • 抑制要因
      • デバイスの高コスト
    • 機会
    • 影響度分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格アナリシス
  • レギュラトリー・アナリシス

第6章 COVID-19の分析

  • 市場におけるCOVID-19の分析
    • COVID-19の市場シナリオの前に
    • 現在のCOVID-19の市場シナリオ
    • COVID-19以降または将来シナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • 結論

第7章 アプリケーションタイプ別

  • アルツハイマー型認知症
  • うつ病
  • パーキンソン病（Parkinson's Disease
  • 癲癇（てんかん
  • その他

第8章 タイプ別

  • Deep Transcranial Magnetic Stimulation（深層頭蓋磁気刺激）
  • 反復経頭蓋磁気刺激法（Repetitive Transcranial Magnetic Stimulation）
  • その他

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • U.K.
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢について

  • 主な発展と戦略
  • 企業シェア分析
  • 製品ベンチマーキング

第12章 企業プロファイル

  • Brainsway
    • 会社概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Magstim
  • Neurosoft
  • MAG & More GmbH
  • Salience TMS Neuro Solutions
  • eNeura Inc.
  • Nexstim, Inc
  • Magventure
  • Eneura
  • Axilum Robotics

第13章 DataM

目次
Product Code: MD1678

Market Overview

The global Transcranial Magnetic Stimulator Market size was valued at US$ 1,125.25 million in 2022 and is estimated to reach US$ 2,244.79 million by 2030, growing at a CAGR of 9.2% during the forecast period (2023-2030).

Transcranial Magnetic Stimulation is a noninvasive technological breakthrough involving applying short magnetic pulses to elicit nerve cells in brain regions associated with major depression, Alzheimer's, Parkinson's and other neurology disorders.

Market Dynamics

The growing geriatric population and increase in age-related neurological disorders, along with product launches and approvals, are boosting the global transcranial magnetic nerve stimulation market growth during the forecast period.

A large number of product launches and approvals drive the forecast period's global market growth.

The growing market developments, such as product launches and approvals, are driving the global transcranial magnetic stimulator market growth during the forecast period. For instance, in July 2022, the FDA approved Neuronetics's NeuroStar Advanced Therapy for Mental Health, a transcranial magnetic stimulation device for treating anxiety symptoms in individuals with major depressive disorder. Likewise, in August 2021, the U.S. FDA approved Deep Transcranial Magnetic Stimulation (Deep TMS) System marketing clearance to BrainsWay Ltd., a supplier of advanced noninvasive neurostimulation treatments for mental health conditions, to lessen anxiety comorbid manifestations with depression in adult patients, also called anxious depression. Similarly, in August 2020, the FDA granted clearance to MagVenture's TMS Therapy for the adjunct treatment of the obsessive-compulsive disorder (OCD). It is the second indication in the U.S. for the Danish medical device company MagVenture.

Moreover, in November 2021, Magstim, a neuroscience-based mental health care and research provider received 510K clearance for Horizon 3.0. Horizon 3.0 delivers enhanced workflows with navigated TMS and analytics since it was particularly designed for the clinical setting. Thereby delivering connected care at networked sites, Magstim Connect is a unique and concentrated patient data management solution for TMS, which is anticipated to enhance market growth in the near future. Therefore, the growing product approvals and launches are boosting the global transcranial magnetic stimulators market during the forecast period.

The high cost of the TMS will likely restrain the growth of the global transcranial magnetic stimulator market.

However, the high cost of the transcranial stimulator machine will restrain the global market growth during the forecast period. For instance, a TMS machine may cost up to $60,000, leaving most individuals or practitioners unable to buy, hampering the global market growth during the forecast period.

COVID-19 Impact

COVID-19 significantly impacted the global transcranial magnetic stimulators market, as the pandemic directly impacted demand and production and raised the financial burden on firms. Neurological procedures were frequently delayed or canceled to stop the spread of COVID-19 during the pandemic. The most-affected nations, the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain, observed around a 55% decline in neurosurgical procedures. The COVID-19 virus can harm the heart, lungs, and brain, which raises the possibility of long-term health issues. However, COVID-19 has led to an increase in cases of depression and anxiety owing to social isolation, which has somewhat neutralized the negative impact of the pandemic.

Segment Analysis

The devices segment is expected to dominate the market throughout the forecast period (2023-2030).

The growing cases of Alzheimer's worldwide and new research developments about TMS in Alzheimer's are boosting the segment growth during the forecast period. For instance, according to Alzheimer's Disease International, someone develops dementia every 3 seconds. There were more than 55 million people worldwide with dementia in 2020. This number will increase nearly twice every 20 years, achieving about 78 million in 2030 and around 139 million in 2050. Considerably the upsurge will be in developing nations. Over 60% of individuals with dementia live in low and middle-income nations, while by 2050, this will increase to roughly 71%. The most rapid growth in the elderly population occurs in China, India, and their south Asian and western Pacific neighbors. Dementia primarily affects older people, although there is a growing understanding of cases that begin before age 65.

Moreover, according to the WHO, above 55 million people live with dementia globally, and there are almost 10 million new cases yearly. Alzheimer's disease is the most typical dementia and makes up 60-70% of cases. Also, according to the BrightFocus, a tax-exempt nonprofit organization, the percentage of people with Alzheimer's boosts with age: about 5% of people aged 65 to 74, around 13% of people aged 75-84, and almost 33% of people aged 85 and older have Alzheimer's dementia. Furthermore, new research suggests that the novel approach to repetitive transcranial magnetic stimulation (rTMS) that targets the precuneus appears to slow the progression of cognitive and functional decline in individuals with Alzheimer's disease (AD). Thus, from the data mentioned the TMS application in Amlzhimers will dominate the global transcranial stimulators market throughout the forecast period.

Geographical Analysis

The North American region holds the largest global Transcranial Magnetic Stimulator Market share.

North America dominates the global transcranial stimulators market owing to the increasing geriatric population, different organizations spreading awareness about neurological disorders, the growing cases of neurological disorders in this region and the presence of better reimbursement policies. For instance, according to America's Health Rankings Senior Report 2021, over 54 million adults aged 65 and older live in the U.S., accounting for approximately 16.5% of the nation's population. The number of older adults in the U.S. is expanding, and by 2050, the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million, roughly 20% of the overall U.S. population. Moreover, according to the Alzheimer's Association, more than 6 million Americans are living with Alzheimer's, which is expected to reach almost 13 million by 2050. That is, 1 in 3 seniors dies with Alzheimer's or another dementia. It kills more than breast cancer and prostate cancer combined. In 2022, Alzheimer's and other dementias were estimated to cost the nation $321 billion, and these costs were anticipated to reach nearly $1 trillion by 2050. Furthermore, transcranial magnetic stimulation therapy is reimbursed by Medicare.gov if provided by the use of a device approved by the FDA to supply TMS. Therefore, from the data mentioned above, it is estimated that North America will hold most of the global transcranial magnetic stimulation market throughout the forecast period.

Competitive Landscape

The Transcranial magnetic stimulator market is moderately competitive due to the new market entrants and favorable regulatory policies. Some key players are Brainsway, Magstim, Neurosoft, MAG & More GmbH, Salience TMS Neuro Solutions, eNeura Inc., Nexstim Inc, Magventure, Eneura, and Axilum Robotics., among others. These key players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in March 2021, MagVenture launched the MagVenture Flow Arm, a patent-pending clinical positioning system developed to enhance the delivery of MagVenture's FDA-cleared protocols for noninvasive brain stimulation technology for the treatment of major depressive disorder and as an adjunct therapy for the obsessive-compulsive disorder (OCD).

BrainsWay

Overview:

BrainsWay is an international company committed to developing a medical device that utilizes H-coil for deep transcranial magnetic stimulation as a non-invasive therapy for depression, OCD, and smoking addiction. The company was established in 2003 and is headquartered in Massachusetts, United States.

Product Portfolio:

BrainsWays' transcranial magnetic stimulator product portfolio has Deep TMS: A revolutionary depression treatment that has transformed the mental healthcare field, Deep TMS has been FDA-approved for safely and effectively treating Major Depressive Disorder (MDD) through BrainsWay's patented H-coil technology..

The global transcranial magnetic stimulator market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. A Large Number of Product Launches and Approvals
      • 4.1.1.2. Growing Geriatric Population and Associated Neurological Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of device
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 7.1.2. Market Attractiveness Index, By Application Type
  • 7.2. Alzheimer's Disease
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. Depression
  • 7.4. Parkinson's Disease
  • 7.5. Epilepsy
  • 7.6. Others

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Deep Transcranial Magnetic Stimulation
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Repetitive Transcranial Magnetic Stimulation
  • 8.4. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Ambulatory Surgery Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Brainsway
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Magstim
  • 12.3. Neurosoft
  • 12.4. MAG & More GmbH
  • 12.5. Salience TMS Neuro Solutions
  • 12.6. eNeura Inc.
  • 12.7. Nexstim, Inc
  • 12.8. Magventure
  • 12.9. Eneura
  • 12.10. Axilum Robotics

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us